Kathleen Wilson
Primary Care · Grand Junction, CONPI 1861936346
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Boston Scientific at 24.3% of the total. Reporting peaked in 2024 at $350 and has fallen 57.2% since, to $150 in 2025.
Across 28 payments — averaging $30.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$206
- AstraZeneca$146
- AbbVie$121
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$91
- Organogenesis Inc.$80
- Lilly USA, LLC$50
- plus $153 from 8 others
What the payments were for
- Food & beverage$848100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 2 | $206 |
| AstraZeneca | 6 | $146 |
| AbbVie | 6 | $121 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $91 |
| Organogenesis Inc. | 1 | $80 |
| Lilly USA, LLC | 3 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Pfizer | 1 | $19 |
| Amgen | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Urgo Medical North America, LLC | 1 | $18 |
| Novo Nordisk | 1 | $14 |
| Abbott | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$848 in reported general payments places this provider in the 70th percentile of 112 primary care providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 19 | $29,132 |
| MounjaroTirzepatide | 15 | $16,536 |
| EliquisApixaban | 11 | $14,598 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $14,081 |
| JardianceEmpagliflozin | 11 | $10,394 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,268 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $3,004 |
| Gabapentin | 45 | $1,583 |
| Pantoprazole Sodium | 61 | $1,525 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,352 |
| Atorvastatin Calcium | 65 | $1,273 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $1,176 |
| Oxycodone Hcl | 73 | $925 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $916 |
| Omeprazole | 20 | $889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $146 | $29,13219 claims |
| Lilly USA, LLCMounjaro | $50 | $16,53615 claims |
| PfizerEliquis | $19 | $14,59811 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $39 | $14,08112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 112 primary care providers in Colorado.
Other primary care in Grand Junction
- Linda MyersGrand Junction$4K
- Laura CarlsenLittleton$22K
- Kendra PayneCastle Rock$22K
- Kaitlin KrausDenver$16K
- Emily WillmannThornton$4K
- Tracy RasmussenParker$4K
- Kathryn PalmerGreeley$4K
- Leah BrownFort Morgan$3K
- Diana Rodriguez OrtizAurora$2K
- Amanda FadenrechtPueblo West$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.